Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

STI-571

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_5510-2

Synonyms

Definition

STI-571 is an oral drug marketed by Novartis and is currently used for the treatment of certain types of cancer(s), including chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST).

Characteristics

Physicochemical Properties

STI-571 is a small compound belonging to the phenylaminopyrimidine class of compounds (Fig. 1). It is chemically designed as 4-[(4-methyl-1-piperazinyl)methyl]- N-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamidine methanesulfonate, with a molecular formula of C 29H 31N 7O·CH 4SO 3. Its molecular weight is 589.72.

Keywords

Chronic Myeloid Leukemia Gastrointestinal Stromal Tumor Blast Crisis Chronic Myeloid Leukemia Cell Central Nervous System Relapse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Baccarani M, Sagoio G, Goldman J et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 108:1809–1820CrossRefPubMedGoogle Scholar
  2. Cohen MH, Johnson JR, Pazdur R (2005) U.S. Food and Drug Administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 11:12–19PubMedGoogle Scholar
  3. Hughes TP, Hochhaus A, Branford S et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758–3765CrossRefPubMedPubMedCentralGoogle Scholar
  4. Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298:1912–1934CrossRefPubMedGoogle Scholar
  5. Peng B, Lioyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879–894CrossRefPubMedGoogle Scholar
  6. Zwan SM, van der DeMatteo RP (2005) Gastrointestinal stromal tumor: 5 years later. Cancer 104:1781–1788CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of HaematologyRoyal Liverpool University HospitalLiverpoolUK